

STRATEGIC SUMMARY FOR THE BOARD OF DIRECTORS

Institution: BN Health Analytics

Prepared For: Board of Directors, Quality & Safety Committee

Prepared By: Department of Cardiology & Clinical Analytics

Classification: For Executive Review-Public Distribution Ready

EXECUTIVE OVERVIEW

Heart attack (acute myocardial infarction) remains one of the most common and resource-intensive conditions managed across our system. This report provides the Board with a clear, data-driven assessment of:

- Who is having heart attacks in our population?
- Where do we have opportunities to improve outcomes?

We are delivering high-quality care, but three specific gaps require strategic attention. Addressing these will save lives, reduce readmissions, and strengthen our market position as a leader in cardiovascular care.

KEY FINDINGS

This study reveals that:

- The heart-disease group is slightly larger than the non-disease group. Roughly 50,00 (53.7%) of patients have heart disease vs 43,000 (46.3%) without.
- Men (68.32%) are more affected than women (31.68%).
- Heart attacks remain more common in older males 60+ but there is a relative increase in middle-aged (40-49) people which is a critical signal.

STRATEGIC RECOMMENDATION

Establish a Cardiovascular Risk Reduction Program focused on men and women with hypertension or diabetes. This program will also include middle-aged person in order to prevent and take care of it earlier when diagnosed. Deploy community-based screening at primary care clinics and senior centers. Goal is 75% reduction in incident heart attacks within 2 years.

Board Action

- Approve pilot program budget (\$750, 000)
- Direct Marketing & Community Relations to develop outreach campaign.
- Review every 3 months progress update.

CLOSING STATEMENT

This is not a story of failure. It is a story of high performance with clear opportunities for excellence. Our cardiology team already delivers survival outcomes that exceed national averages. The investments requested today will close the remaining gaps, save lives, protect our reputation, and strengthen our financial position in an era of value-based reimbursement. We recommend immediate approval and will return to the Board in 12 months with a formal progress report.